Entries by Jules Adam

Angelini partners with Quiver on AI-driven discovery in genetic epilepsies

Italy’s Angelini Pharma has signed a multi-year research collaboration and licensing agreement with Massachusetts-based Quiver Bioscience to discover new treatments for genetic epilepsies, including developmental and epileptic encephalopathies (DEEs). Under the agreement, Quiver could receive up to $120 million in milestone payments plus royalties if Angelini advances drug targets emerging from the collaboration. Financial terms for the upfront payment were not disclosed. Angelini will also receive exclusive access to data generated during the research term.

Microbiotica’s microbiome therapy showed 63% remission in ulcerative colitis phase 1b trial

Cambridge-based Microbiotica’s ulcerative colitis (UC) candidate met its primary and secondary phase 1b study objectives on safety, efficacy signals and bacterial engraftment. The company has reported positive results from a small, placebo-controlled study of its oral precision microbiome therapy MB310 in patients with mild-to-moderate ulcerative colitis, adding a rare positive clinical signal in a disease area where microbiome approaches have so far struggled to gain traction.

PharosAI partners with 10x Genomics on spatial cancer data backed by £18.9 million

PharosAI, a U.K. cancer research consortium bringing together King’s College London, Queen Mary University of London, Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust and Barts Health NHS Trust, has partnered with 10x Genomics to generate large-scale multimodal cancer datasets from archived NHS tumor samples using 10x’s Xenium spatial biology platform.

Poxel takes first step in recovery plan with €5 million equity line

French biotech Poxel is trying to stabilise its business after judicial reorganisation, with its court-approved recovery plan now moving into the execution phase. The Lyon-based company, which has spent the past year under financial pressure, received approval from the Commercial Court of Lyon last week to restructure its debt and continue operations.

Kahimmune launches and secures exclusive license for dark-genome cancer vaccine platform

Newly formed French biotech Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay, securing rights to a technology platform designed to identify tumor antigens derived from the “dark” or non-coding genome. The spin-off, created in late 2025, plans to use the licensed technology to develop shared mRNA cancer vaccines, with an initial program targeting colorectal and pancreatic cancer.